Ditchcarbon
  • Customers
  1. Organizations
  2. Halozyme Therapeutics, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 5 months ago

Halozyme Therapeutics, Inc.

Company website

Halozyme Therapeutics, Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovative drug delivery solutions since its founding in 1998. Specialising in the development of enzyme-based therapies, Halozyme focuses on enhancing the efficacy of biologic drugs through its proprietary Hylenex® recombinant technology, which facilitates the subcutaneous delivery of therapeutics. With a strong presence in the biopharmaceutical industry, Halozyme has established strategic partnerships with major pharmaceutical companies, significantly expanding its market reach. Notable achievements include the successful integration of its technology into various therapeutic areas, including oncology and diabetes care. As a pioneer in the field, Halozyme continues to drive advancements in drug delivery, positioning itself as a key player in the evolving landscape of biotechnology.

DitchCarbon Score

How does Halozyme Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Halozyme Therapeutics, Inc.'s score of 25 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.

26%

Let us know if this data was useful to you

Halozyme Therapeutics, Inc.'s reported carbon emissions

Halozyme Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Halozyme has not inherited any emissions data from a parent or related organization, nor does it have any commitments to industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the biopharmaceutical industry, companies are increasingly focusing on sustainability and climate commitments. However, without specific data or targets, it is unclear how Halozyme Therapeutics aligns with these broader industry trends.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Halozyme Therapeutics, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Halozyme Therapeutics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Halozyme Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Perrigo

IE
•
Pharmaceutical Preparation Manufacturing
Updated about 18 hours ago

Ypsomed

CH
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 18 hours ago

West Pharmaceutical Services

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 18 hours ago

Green Dot

DE
•
Real estate services (70)
Updated about 18 hours ago

Mr. Cooper Group Inc.

US
•
Financial intermediation services, except insurance and pension funding services (65)
Updated 10 days ago

Redwood Trust, Inc.

US
•
Real estate services (70)
Updated 10 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250804.4
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy